Julia Rueb was named Chief Financial Officer of Tyra Biosciences, Inc., effective April 1, 2026. As of November 6, 2026, Tyra Biosciences, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 2, 2026 to April 17, 2026, naming 2 appointments (Form 8-K, April 2, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Tyra Biosciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Tyra Biosciences, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-02 to 2026-04-17. They name 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as Tyra Biosciences, Inc. files it.
Also on the record for Tyra Biosciences, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 4.8% of the class | 5%+ stakes | Source |
| September 21, 2026 | Stake report, Schedule 13G, by BVF PARTNERS L P/IL | 6.1% of the class | 5%+ stakes | Source |
| September 17, 2026 | Stake report, Schedule 13D/A, by RA Capital Management, L.P. | 19.9% of the class | 5%+ stakes | Source |
| September 17, 2026 | Stake report, Schedule 13G, by Paradigm BioCapital Advisors LP | 5.8% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Farallon Capital Management, L.L.C. | — | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Nextech VI Oncology SCSp | 6% of the class | 5%+ stakes | Source |
| July 30, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Commodore Capital LP | 4.2% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 7.2% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G/A, by Todd Harris | 4.8% of the class | 5%+ stakes | Source |
| May 12, 2026 | Stake report, Schedule 13G/A, by Dapice Joshua J. | 6.6% of the class | 5%+ stakes | Source |
| April 24, 2026 | Stake report, Schedule 13G/A, by Canaan XI L.P. | 1.4% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Tyra Biosciences, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Tyra Biosciences, Inc. and the records around it.
Tyra Biosciences, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Canaan XI L.P. also filed stake reports on 1 other company: AEVA TECHNOLOGIES, INC. (Jul 2025)
- Farallon Capital Management, L.L.C. also filed stake reports on 18 other companies: EXELIXIS, INC. (Nov 2026), ENANTA PHARMACEUTICALS INC (Aug 2026), InflaRx N.V. (Aug 2026)
- Farallon Capital Partners, L.P. also filed stake reports on 19 other companies: BridgeBio Pharma, Inc. (May 2026), InflaRx N.V. (May 2026), Beta Bionics, Inc. (May 2026)
Watch Tyra Biosciences, Inc.
Get an email when Tyra Biosciences, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Tyra Biosciences, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Tyra Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Tyra Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 21 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-04-17 | In | Director | 8-K, 2026-04-17 | ||
| 2026-04-02 | In | Chief Financial Officer | 2026-04-01 | 8-K, 2026-04-02 |
Who leads Tyra Biosciences, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Habib J. Dable, appointed (filed 2026-04-17).
- Chief Financial Officer: Julia Rueb, appointed, effective 2026-04-01 (filed 2026-04-02).
New leaders reset buying decisions — get the Full Report on Tyra Biosciences, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Tyra Biosciences, Inc., with the record behind each one.
Find candidates like Director at Tyra Biosciences, Inc.Every change, in the filing's words
Appointed: Habib J. Dable, Director
On April 16, 2026, upon the recommendation of the Nominating and Corporate Governance Committee of the board of directors (the Board) of Tyra Biosciences, Inc. (the Company), and pursuant to the amended and restated bylaws of the Company, the Board approved an increase in the number of authorized directors from nine to ten and appointed Habib J. Dable to the Board as a Class II director with an initial term expiring at the Company's 2026 annual meeting of stockholders.
- Mr. Dable, 56, has served as an advisor at RA Capital Management, L.P., an investment manager, since April 2022.
- Previously, Mr. Dable served as President and Chief Executive Officer of Acceleron Pharma Inc., a biopharmaceutical company, from December 2016 until its acquisition by Merck in November 2021.
- Prior to joining Acceleron, Mr. Dable held roles of increasing responsibility at Bayer AG beginning in 1994, serving as the President of Pharmaceuticals for Bayer in the U.S. from October 2015 until December 2016.
- From 2013 to 2015, Mr. Dable served as the Executive Vice President and Global Head of Specialty Medicine for Bayer HealthCare Pharmaceuticals, and from 2010 to 2012, he was the Vice President of Ophthalmology & Global Launch Team Head for EYLEA.
- Mr. Dable holds a bachelor's degree in business administration and an MBA, each from the University of New Brunswick in Canada.
- In connection with his appointment to the Board, pursuant to the Company's Non-Employee Director Compensation Program, Mr. Dable was granted options to purchase 44,400 shares of the Company's common stock.
- The options have an exercise price per share equal to the fair market value of the Company's common stock on the date of grant.
- The foregoing awards will vest in substantially equal monthly installments over the thirty-six months following the date of grant.
Appointed: Julia Rueb, Chief Financial Officer, effective 2026-04-01
On April 1, 2026, the Board of Directors of Tyra Biosciences, Inc. (the Company) designated Julia Rueb, Vice President, Finance of the Company, as the Company's principal accounting officer, succeeding Alan Fuhrman, the Company's Chief Financial Officer, in that role, each effective as of April 1, 2026.
- Mr. Fuhrman continues to be the Company's principal financial officer.
- Ms. Rueb, 40, has served as Vice President, Finance of the Company since January 2024.
- Previously, Ms. Rueb served as Director and Senior Director of Accounting and Corporate Controller from October 2022 to December 2023.
- From October 2021 to October 2022, Ms. Rueb served as Associate Director and Director, Technical Accounting at SOAProjects, Inc. From October 2020 to October 2021, Ms. Rueb served as a Manager at van den Boom & Associates LLC, where she provided accounting and finance consulting services to various companies, primarily in the life sciences industry, including the Company.
- Earlier in her career, Ms. Rueb was employed at Ernst & Young LLP from 2013 to October 2020, most recently serving as an Audit Manager, where she primarily served public life sciences companies.
- Ms. Rueb holds a Master's degree in Accounting from the University of San Diego and is a Certified Public Accountant.
Tools for this story
Each opens in a new tab, filled in for Tyra Biosciences, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.